New antibody-drug conjugate shows clinical benefit for advanced platinum-resistant ovarian cancer

Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced clinical benefit when treated with the investigational antibody-drug conjugate (ADC) QLS5132, according to results from a phase I clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17–22.